New clinical data suggests that Novera Retatrutide, a dual-action therapy from Novo Nordisk, could offer a meaningful breakthrough in weight management. Beyond many existing treatments, Retatrutide impacts both the GLP-1 hormone and the GIP hormone, potentially resulting to improved reductions in